SCHEMBL109955

SCHEMBL109955

CCCCCc1c[nH]c2ccccc12

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 1/20 0.66
HTR2A P28223 5/20 0.61
HTR1A P08908 4/20 0.61
HTR6 P50406 2/20 0.61
ALOX12 P18054 1/20 0.61
CYP3A4 P08684 3/20 0.61
HTR2C P28335 2/20 0.61
CYP1A2 P05177 2/20 0.61
CYP2D6 P10635 2/20 0.61
MPO P05164 1/20 0.61
CYP2A6 P11509 1/20 0.61
NFKB1 P19838 1/20 0.61
HTR1D P28221 1/20 0.61
HTR1B P28222 1/20 0.61
HTR7 P34969 1/20 0.61
CTSK P43235 1/20 0.61
CYP2A13 Q16696 1/20 0.61
TAAR1 Q96RJ0 1/20 0.61
MTNR1A P48039 2/20 0.60
SMN1; SMN2 Q16637 2/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20648101 0.98 SLC6A4 (0.64) SLC6A4HTR2AHTR1AHTR6ALOX12
SCHEMBL1563873 0.98 SLC6A4 (0.64) SLC6A4HTR2AHTR1AHTR6ALOX12
SCHEMBL22582285 0.98 SLC6A4 (0.64) SLC6A4HTR2AHTR1AHTR6ALOX12
SCHEMBL24961938 0.98 SLC6A4 (0.64) SLC6A4HTR2AHTR1AHTR6ALOX12
SCHEMBL8079335 0.98 SLC6A4 (0.64) SLC6A4HTR2AHTR1AHTR6ALOX12
SCHEMBL25140788 0.98 SLC6A4 (0.64) SLC6A4HTR2AHTR1AHTR6ALOX12
SCHEMBL13856893 0.98 SLC6A4 (0.64) SLC6A4HTR2AHTR1AHTR6ALOX12
SCHEMBL266641 0.95 SLC6A4 (0.68) SLC6A4HTR2AHTR1AHTR6CYP3A4
Ammonia Solution, Strong SCHEMBL10491416 0.93 SLC6A4 (0.66) SLC6A4HTR2AHTR1AHTR6CYP3A4
SCHEMBL7004146 0.91 HTR2A (0.71) SLC6A4HTR2AHTR1AHTR6CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 207 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250382268-A1 METHODS AND COMPOSITIONS FOR SELECTIVELY INHIBITING PATHOGENIC MICROBES CFD RES CORPORATION (US) 2025-12-18 US claimed
CN-116082216-A 3-aryl indole KDM1A/HDACs double-target inhibitor, and preparation method and application thereof 阜外华中心血管病医院 2023-05-09 CN claimed
CN-109438318-B Synthesis method of 3-aryl indole and derivatives thereof 湖南医药学院 2022-05-03 CN claimed
CN-110498757-B Synthesis method of metal-free 3-acyl indole compound 中国科学院兰州化学物理研究所 2022-03-15 CN claimed
CN-110627705-A N-benzyl indole thiosemicarbazone derivative, preparation and application 西北农林科技大学 2019-12-31 CN claimed
US-20110065715-A1 Nogo Receptor Binding Small Molecules to Promote Axonal Growth YALE UNIVERSITY (US) 2011-03-17 US claimed
EP-2220499-A2 NOGO RECEPTOR BINDING SMALL MOLECULES TO PROMOTE AXONAL GROWTH Yale University (US) 2010-08-25 EP claimed
EP-2195440-A2 BIOFUEL PRODUCTION Bio Architecture Lab, Inc. (US) 2010-06-16 EP claimed
WO-2009073141-A2 NOGO RECEPTOR BINDING SMALL MOLECULES TO PROMOTE AXONAL GROWTH STRITTMATTER STEPHEN M (US) 2009-06-11 WO claimed
WO-2009046375-A2 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-04-09 WO claimed
WO-2009046370-A2 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-04-09 WO claimed
EP-1509250-B1 METHODS COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR MODULATING BONE GROWTH YISSUM RES DEV CO (IL) 2008-05-07 EP claimed
US-6515141-B1 Process for the preparation of indole derivatives or salts thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-02-04 US claimed
EP-1207153-A1 PROCESS FOR THE PREPARATION OF INDOLE DERIVATIVES OR SALTS THEREOF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-05-22 EP claimed
US-5393761-A Treatment of nervous system disorders H. LUNDBECK A/S (DK) 1995-02-28 US claimed
EP-0470039-B1 Novel 3-arylindole and 3-arylindazole derivatives LUNDBECK & CO AS H (DK) 1994-12-07 EP claimed
EP-0621781-A1 USE OF 3-ARYLINDOLE AND 3-ARYLINDAZOLE DERIVATIVES FOR THE TREATMENT OF PSYCHOSES H. LUNDBECK A/S (DK) 1994-11-02 EP claimed
WO-1993014758-A1 USE OF 3-ARYLINDOLE AND 3-ARYLINDAZOLE DERIVATIVES FOR THE TREATMENT OF PSYCHOSES H. LUNDBECK A/S (DK) 1993-08-05 WO claimed
EP-0470039-A2 Novel 3-arylindole and 3-arylindazole derivatives H. LUNDBECK A/S (DK) 1992-02-05 EP claimed
JP-63166877-A None JP disclosed
US-20250382268-A1 METHODS AND COMPOSITIONS FOR SELECTIVELY INHIBITING PATHOGENIC MICROBES CFD RES CORPORATION (US) 2025-12-18 US disclosed
US-20250382269-A1 METHODS AND COMPOSITIONS FOR SELECTIVELY INHIBITING PATHOGENIC MICROBES CFD RES CORPORATION (US) 2025-12-18 US disclosed
CN-117342996-A Preparation and application of trans-2, 3-diacyl indoline compounds 郑州大学 2024-01-05 CN disclosed
EP-4276534-A1 MASK BLANK, RESIST PATTERN FORMING PROCESS AND CHEMICALLY AMPLIFIED POSITIVE RESIST COMPOSITION Shin-Etsu Chemical Co., Ltd. (JP) 2023-11-15 EP disclosed
CN-116903514-A Preparation method of 3-aryl indole-2-ketone compound 西北大学 2023-10-20 CN disclosed
CN-116082217-B N-axis chiral bisindole compound and synthesis method thereof 江苏师范大学 2023-07-14 CN disclosed
WO-2023129976-A1 SALT AND SOLID FORMS OF KETANSERIN TERRAN BIOSCIENCES, INC. (US) 2023-07-06 WO disclosed
CN-116082216-A 3-aryl indole KDM1A/HDACs double-target inhibitor, and preparation method and application thereof 阜外华中心血管病医院 2023-05-09 CN disclosed
CN-116082217-A N-axis chiral bisindole compound and synthesis method thereof 江苏师范大学 2023-05-09 CN disclosed
CN-115677674-A Preparation method of heterocyclic compound containing indolone and 3-acyl benzofuran or indole structure 浙江理工大学 2023-02-03 CN disclosed
CN-113336689-B Synthesis method and anticancer activity of 3- (alpha-fluorovinyl/carbonyl) indole compound 河南师范大学 2022-06-17 CN disclosed
CN-114436943-A Method for synthesizing spiro indole compound through double oxidative dehydroaromatization 河南师范大学 2022-05-06 CN disclosed
CN-109438318-B Synthesis method of 3-aryl indole and derivatives thereof 湖南医药学院 2022-05-03 CN disclosed
CN-109438318-B Synthesis method of 3-aryl indole and derivatives thereof 湖南医药学院 2022-05-03 CN disclosed
CN-109438318-B Synthesis method of 3-aryl indole and derivatives thereof 湖南医药学院 2022-05-03 CN disclosed
CN-114394891-A Compound prepared by catalyzing chalcone with monovalent iodine reagent, and preparation method and application thereof 化学与精细化工广东省实验室 2022-04-26 CN disclosed
CN-110498757-B Synthesis method of metal-free 3-acyl indole compound 中国科学院兰州化学物理研究所 2022-03-15 CN disclosed
CN-110498757-B Synthesis method of metal-free 3-acyl indole compound 中国科学院兰州化学物理研究所 2022-03-15 CN disclosed
CN-110498757-B Synthesis method of metal-free 3-acyl indole compound 中国科学院兰州化学物理研究所 2022-03-15 CN disclosed
WO-2021250059-A1 METHOD FOR SYNTHESIS OF THIOETHER-CONTAINING PEPTIDES HEIDELBERG PHARMA RESEARCH GMBH (DE) 2021-12-16 WO disclosed
CN-113336689-A Synthesis method and anticancer activity of 3- (alpha-fluorovinyl/carbonyl) indole compound 河南师范大学 2021-09-03 CN disclosed
CN-109232361-B Synthesis method of C3-carbonyl acetyl indole derivative 华南理工大学 2021-08-10 CN disclosed
CN-110627705-B N-benzyl indole thiosemicarbazone derivative, preparation and application 西北农林科技大学 2021-07-16 CN disclosed
CN-108624633-B Preparation method and application of indole-3-formaldehyde 中国热带农业科学院海口实验站 2021-05-18 CN disclosed
CN-108752256-B Preparation method of N-acyl indole compound based on carboxylic acid alkenyl ester as acylation reagent 六盘水师范学院 2021-04-13 CN disclosed
WO-2020205934-A1 PYRROLE COMPOUNDS ALIGOS THERAPEUTICS, INC. (US) 2020-10-08 WO disclosed
US-10752585-B2 Process for the preparation of Zafirlukast and analogs thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2020-08-25 US disclosed
US-20200223826-A1 Glucose-6-Phosphate Dehydrogenase (G6PD)-Modulating Agents And Methods Of Treating G6PD Deficiency THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2020-07-16 US disclosed
US-20200216390-A1 PROCESS FOR THE PREPARATION OF ZAFIRLUKAST AND ANALOGS THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2020-07-09 US disclosed
CN-110627705-A N-benzyl indole thiosemicarbazone derivative, preparation and application 西北农林科技大学 2019-12-31 CN disclosed
EP-3519567-A1 ENGINEERED MICROORGANISMS FOR PRODUCTION OF COMMODITY CHEMICALS AND CELLULAR BIOMASS The Regents of The University of California (US) 2019-08-07 EP disclosed
CN-110054579-A A kind of preparation method and applications of 4- (1-H indoles) phenol derivatives 贵州省中国科学院天然产物化学重点实验室 2019-07-26 CN disclosed
US-10266526-B2 Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer Epizyme, Inc. (US) 2019-04-23 US disclosed
CN-109232361-A A kind of synthetic method of C3- carbonyl acetyl indole derivative 华南理工大学 2019-01-18 CN disclosed
US-20180312493-A1 Antibiotic Compounds, Pharmaceutical Formulations Thereof And Methods And Uses Therefor CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) 2018-11-01 US disclosed
WO-2018151833-A1 HIGH PRESSURE ZONE FORMATION FOR PRETREATMENT SWEETWATER ENERGY, INC. (US) 2018-08-23 WO disclosed
WO-2018067458-A1 ENGINEERED MICROORGANISMS FOR PRODUCTION OF COMMODITY CHEMICALS AND CELLULAR BIOMASS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-04-12 WO disclosed
WO-2018018863-A1 MILD AND EFFICIENT PREPARATION METHOD FOR Α-ACYLOXY ALKENYL AMIDE COMPOUND AND USE THEREOF IN SYNTHESIS OF AMIDE AND POLYPEPTIDE 江西师范大学 2018-02-01 WO disclosed
US-20170355695-A1 SMYD Inhibitors Epizyme, Inc. (US) 2017-12-14 US disclosed
WO-2017200970-A1 POTENT AND SELECTIVE MU OPIOID RECEPTOR MODULATORS VIRGINIA COMMONWEALTH UNIVERSITY (US) 2017-11-23 WO disclosed
US-20170325457-A1 FORMULATIONS FOR THE DELIVERY OF ACTIVE AGENTS TO INSECTS, PLANTS, AND PLANT PATHOGENS Preceres Inc. (US) 2017-11-16 US disclosed
EP-3230463-A1 RAPID PRETREATMENT Sweetwater Energy, Inc. (US) 2017-10-18 EP disclosed
WO-2017075694-A1 ANTIBIOTIC COMPOUNDS, PHARMACEUTICAL FORMULATIONS THEREOF AND METHODS AND USES THEREFOR SIMON FRASER UNIVERSITY (CA) 2017-05-11 WO disclosed
WO-2016094594-A1 RAPID PRETREATMENT SWEETWATER ENERGY, INC. (US) 2016-06-16 WO disclosed
EP-1294699-B1 MODULATORS OF TNF- ALPHA SIGNALLING GENZYME CORP (US) 2016-04-13 EP disclosed
WO-2015179243-A1 SUGAR SEPARATION AND PURIFICATION THROUGH FILTRATION SWEETWATER ENERGY, INC. (US) 2015-11-26 WO disclosed
EP-2836602-A1 METHODS AND SYSTEMS FOR SACCHARIFICATION OF BIOMASS Sweetwater Energy, Inc. (US) 2015-02-18 EP disclosed
WO-2014190294-A1 SUGAR SEPARATION AND PURIFICATION FROM BIOMASS SWEETWATER ENERGY, INC. (US) 2014-11-27 WO disclosed
WO-2014169079-A2 INCREASED PRODUCTIVITY DURING FERMENTATION SWEETWATER ENERGY, INC. (US) 2014-10-16 WO disclosed
WO-2014143753-A1 CARBON PURIFICATION OF CONCENTRATED SUGAR STREAMS DERIVED FROM PRETREATED BIOMASS SWEETWATER ENERGY, INC. (US) 2014-09-18 WO disclosed
WO-2014026154-A1 OPTIMIZED PRETREATMENT OF BIOMASS SWEETWATER ENERGY, INC. (US) 2014-02-13 WO disclosed
WO-2013155496-A1 METHODS AND SYSTEMS FOR SACCHARIFICATION OF BIOMASS SWEETWATER ENERGY, INC. (US) 2013-10-17 WO disclosed
WO-2013148415-A1 ENHANCED FERMENTATION FROM PRETREATMENT PRODUCTS SWEETWATER ENERGY, INC. (US) 2013-10-03 WO disclosed
WO-2013115959-A1 METHODS AND COMPOSITIONS FOR GROWTH OF YEAST ON ALGINATE BIO ARCHITECTURE LAB, INC. (US) 2013-08-08 WO disclosed
WO-2013085555-A2 MODULATION OF FERMENTATION PRODUCTS THROUGH VITAMIN SUPPLEMENTATION QTEROS, INC. (US) 2013-06-13 WO disclosed
US-20120270827-A1 Indole Antiviral Compositions And Methods THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2012-10-25 US disclosed
WO-2012103385-A2 BIOCATALYSTS SYNTHESIZING DEREGULATED CELLULASES QTEROS, INC. (US) 2012-08-02 WO disclosed
CN-102127002-B Method for preparing 3,3-diaryl substituted and 3-alkyl-3-aryl substituted oxoindole derivative UNIV EAST CHINA NORMAL 2012-06-27 CN disclosed
WO-2012083244-A2 BIOFUEL PRODUCTION USING BIOFILM IN FERMENTATION QTEROS, INC. (US) 2012-06-21 WO disclosed
US-8202844-B2 Indole antiviral compositions and methods THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2012-06-19 US disclosed
WO-2012068537-A2 NEW BIOCATALYSTS AND PRIMERS FOR PRODUCTION OF CHEMICALS QTEROS, INC. (US) 2012-05-24 WO disclosed
EP-2424982-A1 ADAPTING MICROORGANISMS FOR AGRICULTURAL PRODUCTS De Crecy, Eudes (US) 2012-03-07 EP disclosed
EP-2421984-A1 COMPOSITIONS AND METHODS FOR FERMENTATION OF BIOMASS Qteros, Inc. (US) 2012-02-29 EP disclosed
EP-1951225-B1 3-ACYLINDOLE DERIVATIVES THE PREPARATION AND THE THERAPEUTIC USE THEREOF SANOFI SA (FR) 2012-02-01 EP disclosed
EP-2406381-A1 PRODUCTION OF FERMENTIVE END PRODUCTS FROM CLOSTRIDIUM SP. Qteros, Inc. (US) 2012-01-18 EP disclosed
WO-2011149956-A2 METHODS FOR PRODUCING CHEMICAL PRODUCTS FROM FERMENTATION BYPRODUCTS QTEROS, INC. (US) 2011-12-01 WO disclosed
WO-2011137401-A2 REDIRECTED BIOENERGETICS IN RECOMBINANT CELLULOLYTIC CLOSTRIDIUM MICROORGANISMS QTEROS, INC. (US) 2011-11-03 WO disclosed
WO-2011133984-A2 NEW BACTERIUM FOR PRODUCTION OF CHEMICALS AND RECOMBINANTS THEREOF QTEROS, INC. (US) 2011-10-27 WO disclosed
WO-2011133952-A2 NEW BACTERIUM FOR PRODUCTION OF CHEMICALS AND RECOMBINANTS THEREOF QTEROS, INC. (US) 2011-10-27 WO disclosed
WO-2011116358-A2 MICROORGANISMS WITH INACTIVATED LACTATE DEHYDROGENASE GENE (LDH) FOR CHEMICAL PRODUCTION QTEROS INC. (US) 2011-09-22 WO disclosed
US-20110178038-A1 Indole Antiviral Compositions And Methods THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2011-07-21 US disclosed
WO-2010123932-A9 COMPOSITIONS AND METHODS FOR FERMENTATION OF BIOMASS QTEROS, INC. (US) 2011-06-09 WO disclosed
US-7928080-B2 Indole antiviral compositions and methods THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2011-04-19 US disclosed
WO-2010104896-A9 PRODUCTION OF FERMENTIVE END PRODUCTS FROM CLOSTRIDIUM SP. QTEROS, INC. (US) 2011-04-14 WO disclosed
US-20110065715-A1 Nogo Receptor Binding Small Molecules to Promote Axonal Growth YALE UNIVERSITY (US) 2011-03-17 US disclosed
WO-2011008564-A2 COMPOSITIONS AND METHODS FOR IMPROVED SACCHARIFICATION OF BIOMASS QTEROS, INC. (US) 2011-01-20 WO disclosed
WO-2011002824-A1 PRETREATMENT OF BIOMASS QTEROS, INC. (US) 2011-01-06 WO disclosed
WO-2010127182-A1 ADAPTING MICROORGANISMS FOR AGRICULTURAL PRODUCTS EVOLUGATE, LLC (US) 2010-11-04 WO disclosed
WO-2010124147-A1 COMPOSITIONS AND METHODS FOR METHANE PRODUCTION QTEROS, INC. (US) 2010-10-28 WO disclosed
WO-2010123932-A1 COMPOSITIONS AND METHODS FOR FERMENTATION OF BIOMASS QTEROS, INC. (US) 2010-10-28 WO disclosed
WO-2010104896-A1 PRODUCTION OF FERMENTIVE END PRODUCTS FROM CLOSTRIDIUM SP. QTEROS, INC. (US) 2010-09-16 WO disclosed
EP-2220499-A2 NOGO RECEPTOR BINDING SMALL MOLECULES TO PROMOTE AXONAL GROWTH Yale University (US) 2010-08-25 EP disclosed
US-7741363-B2 3-Acylindole derivatives, preparation and therapeutic use thereof SANOFI-AVENTIS (FR) 2010-06-22 US disclosed
EP-2195440-A2 BIOFUEL PRODUCTION Bio Architecture Lab, Inc. (US) 2010-06-16 EP disclosed
US-20090318446-A1 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy CYCLACEL LIMITED (GB) 2009-12-24 US disclosed
US-7625871-B2 Indole antiviral compositions and methods THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2009-12-01 US disclosed
US-20090281052-A1 Indole Antiviral Compositions And Methods THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2009-11-12 US disclosed
WO-2009073141-A2 NOGO RECEPTOR BINDING SMALL MOLECULES TO PROMOTE AXONAL GROWTH STRITTMATTER STEPHEN M (US) 2009-06-11 WO disclosed
WO-2009046375-A2 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-04-09 WO disclosed
WO-2009046370-A2 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-04-09 WO disclosed
US-20080275102-A1 3-ACYLINDOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2008-11-06 US disclosed
US-7419963-B2 Indole antiviral compositions and methods NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2008-09-02 US disclosed
EP-1951225-A2 3-ACYLINDOLE DERIVATIVES THE PREPARATION AND THE THERAPEUTIC USE THEREOF sanofi-aventis (FR) 2008-08-06 EP disclosed
US-20080146517-A1 Indole Antiviral Compositions And Methods THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2008-06-19 US disclosed
US-20080090871-A1 CANNABIMIMETIC INDOLE DERIVATIVES MAKRIYANNIS ALEXANDROS 2008-04-17 US disclosed
CN-100351234-C Bis-heterocyclic compounds with antitumour and chemosensitising activity SIGMA TAU IND FARMACEUTI (IT) 2007-11-28 CN disclosed
EP-1836194-A1 4- (1H-INDOL-3-YL) -PYRIMIDIN-2-YLAMINE DERIVATES AND THEIR USE IN THERAPY Cyclacel Limited (GB) 2007-09-26 EP disclosed
US-7241799-B2 Cannabimimetic indole derivatives UNIVERSITY OF CONNECTICUT (US) 2007-07-10 US disclosed
WO-2007057571-A2 3-ACYLINDOLE DERIVATIVES THE PREPARATION AND THE THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2007-05-24 WO disclosed
US-20070082872-A1 Indole-containing compounds with anti-tubulin and vascular targeting activity BAYLOR UNIVERSITY 2007-04-12 US disclosed
EP-1702617-A1 Cannabimimetic indole derivatives THE UNIVERSITY OF CONNECTICUT (US) 2006-09-20 EP disclosed
EP-1223929-B1 CANNABIMIMETIC INDOLE DERIVATIVES UNIV CONNECTICUT (US) 2006-08-23 EP disclosed
US-20060172019-A1 Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders ABERDEEN, THE UNIVERSITY COURT OF THE UNIVERSITY OF (GB) 2006-08-03 US disclosed
WO-2006075152-A1 4- (1H-INDOL-3-YL) -PYRIMIDIN-2-YLAMINE DERIVATES AND THEIR USE IN THERAPY CYCLACEL LIMITED (GB) 2006-07-20 WO disclosed
EP-1677784-A1 INDOLE ANTIVIRAL COMPOSITIONS AND METHODS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2006-07-12 EP disclosed
CN-1247589-C Tricyclic derivatives of indole with antiangiogenic activity SIGMA TAU IND FARMACEUTI (IT) 2006-03-29 CN disclosed
CN-1733722-A Bis-heterocyclic compounds with antitumour and chemosensitising activity SIGMA TAU IND FARMACEUTI (IT) 2006-02-15 CN disclosed
US-6995184-B2 Such as (7-chloro-2-methyl-1-(3-(methylsulphanyl)propyl)-1H-indol-3-yl)(2,3-dichloro-phenyl)methanone; cannabinoid receptors (cb2); G proteins coupled receptors SANOFI-AVENTIS (FR) 2006-02-07 US disclosed
CN-1234688-C 3-aroyl indoles and their use as CB2Use of receptor agonists SANOFI ANVANT (FR) 2006-01-04 CN disclosed
EP-1606019-A1 CANNABINOID RECEPTOR INVERSE AGONISTS AND NEUTRAL ANTAGONISTS AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE DISORDERS The University Court of The University of Aberdeen (GB) 2005-12-21 EP disclosed
CN-1232518-C Bis-heterocyclic compounds with antitumor and chemosensitive activity SIGMA TAU IND FARMACEUTI (IT) 2005-12-21 CN disclosed
US-20050143329-A1 Indole antiviral compositions and methods THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2005-06-30 US disclosed
US-20050124620-A1 Indole derivatives having an acidic moiety that inhibit or modulate activity of p38 map kinase mediating a disease state; e.g., 3-(2-(4-pyridyl)ethyl)-5-(3-trifluoromethoxybenzamido)indole; enzyme inhibitors; antiarthritic, -inflammatory, and -carcinogenic agents; respiratory disorders; AIDS; Alzheimer's FREDERICKSON MARTYN (GB) 2005-06-09 US disclosed
US-20050119234-A1 Cannabimimetic indole derivatives UNIVERSITY OF CONNECTICUT (US) 2005-06-02 US disclosed
US-6900236-B1 Cannabimimetic indole derivatives UNIVERSITY OF CONNECTICUT (US) 2005-05-31 US disclosed
WO-2005034943-A1 INDOLE ANTIVIRAL COMPOSITIONS AND METHODS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2005-04-21 WO disclosed
US-6858739-B2 Indole and benzimidazole 15-lipoxygenase inhibitors WARNER-LAMBERT COMPANY (US) 2005-02-22 US disclosed
US-20050009903-A1 CB2-selective cannabinoid analogues CLEMSON UNIVERSITY 2005-01-13 US disclosed
EP-1495016-A2 HETEROCYCLIC COMPOUNDS AND THEIR USE AS MODULATORS OF P38 MAP KINASE Astex Technology Limited (GB) 2005-01-12 EP disclosed
EP-0976732-B1 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES EISAI CO LTD (JP) 2004-11-24 EP disclosed
WO-2004099139-A1 INDOLE-CONTAINING COMPOUNDS WITH ANTI-TUBULIN AND VASCULAR TARGETING ACTIVITY BAYLOR UNIVERSITY (US) 2004-11-18 WO disclosed
WO-2004078261-A1 CANNABINOID RECEPTOR INVERSE AGONISTS AND NEUTRAL ANTAGONISTS AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE DISORDERS THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) 2004-09-16 WO disclosed
CN-1483023-A 3-arylindole derivatives and their use as cb2 receptor agonists ʥŵ��-�ϳ�ʵ���ҹ�˾ 2004-03-17 CN disclosed
US-20040038943-A1 Indole and benzimidazole 15-lipoxygenase inhibitors CONNOR DAVID THOMAS (US) 2004-02-26 US disclosed
CN-1473150-A Bis-heterocyclic compounds with antitumor and chemosensitive activity ϣ��������ҩ��ҵ��˾ 2004-02-04 CN disclosed
CN-1471535-A Tricyclic derivatives of indole with antiangiogenic activity ϣ��������ҩ��ҵ��˾ 2004-01-28 CN disclosed
WO-2003087087-A2 HETEROCYCLIC COMPOUNDS AND THEIR USE AS MODULATORS OF P38 MAP KINASE ASTEX TECHNOLOGY LIMITED (GB) 2003-10-23 WO disclosed
EP-0772592-B1 1H-INDOLE-1-FUNCTIONAL sPLA 2 INHIBITORS LILLY CO ELI (US) 2003-05-02 EP disclosed
EP-1294686-A2 INDOLE DERIVATIVES AND THEIR USE AS 15-LIPOXYGENASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2003-03-26 EP disclosed
EP-1088817-B1 Process for the preparation of 3-acyl-indoles PFIZER LTD (GB) 2003-02-26 EP disclosed
US-6515141-B1 Process for the preparation of indole derivatives or salts thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-02-04 US disclosed
US-6515141-B1 Process for the preparation of indole derivatives or salts thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-02-04 US disclosed
CN-1382123-A Process for preparation of indole derivatives or salts thereof FUJISAWA PHARMACEUTICAL CO (JP) 2002-11-27 CN disclosed
EP-1207153-A1 PROCESS FOR THE PREPARATION OF INDOLE DERIVATIVES OR SALTS THEREOF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-05-22 EP disclosed
EP-1207153-A1 PROCESS FOR THE PREPARATION OF INDOLE DERIVATIVES OR SALTS THEREOF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-05-22 EP disclosed
WO-2001096299-A2 INDOLE DERIVATIVES AND THEIR USE AS 15-LIPOXYGENASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-12-20 WO disclosed
EP-0821685-B1 INDOLE-3-CARBONYL AND INDOLE-3-SULFONYL DERIVATIVES AS PLATELET ACTIVATING FACTOR ANTAGONISTS ABBOTT LAB (US) 2001-10-04 EP disclosed
EP-1088817-A3 Process for the preparation of 3-acyl-indoles Pfizer Limited (GB) 2001-08-29 EP disclosed
EP-0823903-B1 HETEROCYCLIC DIARYL COMPOUNDS, PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME, AND USES THEREOF CT INTERNAT DE RECH S (FR) 2001-07-18 EP disclosed
EP-1088817-A2 Process for the preparation of 3-acyl-indoles Pfizer Limited (GB) 2001-04-04 EP disclosed
WO-2001016101-A1 PROCESS FOR THE PREPARATION OF INDOLE DERIVATIVES OR SALTS THEREOF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-03-08 WO disclosed
US-5936098-A Process for producing indoline compounds and intermediates for the production of the same TOKYO TANABE COMPANY LIMITED (JP) 1999-08-10 US disclosed
EP-0595924-B1 PLATELET ACTIVATING FACTOR ANTAGONISTS ABBOTT LAB (US) 1999-04-14 EP disclosed
EP-0772592-A4 1H-INDOLE-1-FUNCTIONAL sPLA 2? INHIBITORS LILLY CO ELI (US) 1998-07-08 EP disclosed
EP-0810214-A4 PROCESS FOR PRODUCING INDOLINE COMPOUNDS AND INTERMEDIATES FOR THE PRODUCTION OF THE SAME TOKYO TANABE CO (JP) 1998-06-10 EP disclosed
US-5726307-A Benzo-fused lactams promote release of growth hormone MERCK & CO., INC. (US) 1998-03-10 US disclosed
EP-0821685-A1 INDOLE-3-CARBONYL AND INDOLE-3-SULFONYL DERIVATIVES AS PLATELET ACTIVATING FACTOR ANTAGONISTS ABBOTT LABORATORIES (US) 1998-02-04 EP disclosed
EP-0810214-A1 PROCESS FOR PRODUCING INDOLINE COMPOUNDS AND INTERMEDIATES FOR THE PRODUCTION OF THE SAME TOKYO TANABE COMPANY LIMITED (JP) 1997-12-03 EP disclosed
EP-0810214-A1 PROCESS FOR PRODUCING INDOLINE COMPOUNDS AND INTERMEDIATES FOR THE PRODUCTION OF THE SAME TOKYO TANABE COMPANY LIMITED (JP) 1997-12-03 EP disclosed
US-5643922-A Indole cyclohexyl platelet activating factor antagonists ABBOTT LABORATORIES (US) 1997-07-01 US disclosed
US-5641800-A ALLEVIATE EFFECT OF SEPTIC SHOCK, ADULT RESPIRATORY DISTRESS SYNDROME, PANCREATITIS, TRAUMA, BRONCHIAL ASTHMA, ALLERGIC RHINITIS, AND RHEUMATOID ARTHRITIS ELI LILLY AND COMPANY (US) 1997-06-24 US disclosed
US-5639780-A NON-STEROIDAL ANTIINFLAMMATORY AGENTS MERCK FROSST CANADA, INC. (CA) 1997-06-17 US disclosed
EP-0772592-A1 1H-INDOLE-1-FUNCTIONAL sPLA 2? INHIBITORS ELI LILLY AND COMPANY (US) 1997-05-14 EP disclosed
WO-1996037467-A1 N-BENZYLINDOL-3-YL BUTANOIC ACID DERIVATIVES AS CYCLOOXYGENASE-2 INHIBITORS MERCK FROSST CANADA INC. (CA) 1996-11-28 WO disclosed
WO-1996033196-A1 INDOLE-3-CARBONYL AND INDOLE-3-SULFONYL DERIVATIVES AS PLATELET ACTIVATING FACTOR ANTAGONISTS ABBOTT LABORATORIES (US) 1996-10-24 WO disclosed
US-5567711-A Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet activating factor antagonists ABBOTT LABORATORIES (US) 1996-10-22 US disclosed
WO-1996025396-A1 PROCESS FOR PRODUCING INDOLINE COMPOUNDS AND INTERMEDIATES FOR THE PRODUCTION OF THE SAME TOKYO TANABE COMPANY LIMITED (JP) 1996-08-22 WO disclosed
US-5502065-A TREATING HEADACHES PFIZER INC. (US) 1996-03-26 US disclosed
WO-1996003376-A1 1H-INDOLE-1-FUNCTIONAL sPLA2 INHIBITORS ELI LILLY AND COMPANY (US) 1996-02-08 WO disclosed
US-5459152-A 3-(pyridin-3-yl)-7-(indol-3-yl)carbonyl-1H,3H-pyrrolo(1,2-c) thiazole derivatives; asthma ABBOTT LABORATORIES (US) 1995-10-17 US disclosed
US-5393761-A Treatment of nervous system disorders H. LUNDBECK A/S (DK) 1995-02-28 US disclosed
US-5393761-A Treatment of nervous system disorders H. LUNDBECK A/S (DK) 1995-02-28 US disclosed
EP-0636129-A1 INDOLE DERIVATIVES AS 5-HT1-LIKE AGONISTS Pfizer Limited (GB) 1995-02-01 EP disclosed
US-5374721-A Benzo-fused lactams promote release of growth hormone MERCK & CO., INC. (US) 1994-12-20 US disclosed
EP-0470039-B1 Novel 3-arylindole and 3-arylindazole derivatives LUNDBECK & CO AS H (DK) 1994-12-07 EP disclosed
EP-0470039-B1 Novel 3-arylindole and 3-arylindazole derivatives LUNDBECK & CO AS H (DK) 1994-12-07 EP disclosed
EP-0621781-A1 USE OF 3-ARYLINDOLE AND 3-ARYLINDAZOLE DERIVATIVES FOR THE TREATMENT OF PSYCHOSES H. LUNDBECK A/S (DK) 1994-11-02 EP disclosed
EP-0595924-A4 PLATELET ACTIVATING FACTOR ANTAGONISTS ABBOTT LAB (US) 1994-08-24 EP disclosed
EP-0547178-A4 NOVEL CHOLECYSTOKININ ANTAGONISTS, THEIR PREPARATION AND THERAPEUTIC USE WARNER LAMBERT CO (US) 1994-07-06 EP disclosed
EP-0595924-A1 PLATELET ACTIVATING FACTOR ANTAGONISTS ABBOTT LABORATORIES (US) 1994-05-11 EP disclosed
WO-1993021178-A1 INDOLE DERIVATIVES AS 5-HT1-LIKE AGONISTS PFIZER LIMITED (GB) 1993-10-28 WO disclosed
WO-1993014758-A1 USE OF 3-ARYLINDOLE AND 3-ARYLINDAZOLE DERIVATIVES FOR THE TREATMENT OF PSYCHOSES H. LUNDBECK A/S (DK) 1993-08-05 WO disclosed
WO-1993014758-A1 USE OF 3-ARYLINDOLE AND 3-ARYLINDAZOLE DERIVATIVES FOR THE TREATMENT OF PSYCHOSES H. LUNDBECK A/S (DK) 1993-08-05 WO disclosed
EP-0547178-A1 NOVEL CHOLECYSTOKININ ANTAGONISTS, THEIR PREPARATION AND THERAPEUTIC USE WARNER-LAMBERT COMPANY (US) 1993-06-23 EP disclosed
WO-1993001813-A1 PLATELET ACTIVATING FACTOR ANTAGONISTS ABBOTT LABORATORIES (US) 1993-02-04 WO disclosed
EP-0470039-A2 Novel 3-arylindole and 3-arylindazole derivatives H. LUNDBECK A/S (DK) 1992-02-05 EP disclosed
EP-0470039-A2 Novel 3-arylindole and 3-arylindazole derivatives H. LUNDBECK A/S (DK) 1992-02-05 EP disclosed
EP-0238226-B1 Substituted 1,3,4,9-tetrahydropyrano [3,4-b]indole-1-acetic acids AMERICAN HOME PRODUCTS CORPORATION (US) 1990-12-05 EP disclosed
US-4971960-A ANTIINFLAMMATORY AGENTS, ANALGESICS AMERICAN HOME PRODUCTS CORPORATION (US) 1990-11-20 US disclosed
US-4826994-A FROM ISATIN AMERICAN HOME PRODUCTS CORPORATION (US) 1989-05-02 US disclosed
US-4775690-A ANALGESICS, ANTIINFLAMMATORY AGENTS AMERICAN HOME PRODUCTS CORPORATION (US) 1988-10-04 US disclosed
JP-S63166877-A FULGIDE BASED PHOTOCHROMIC COMPOUND YAMAHA CORP 1988-07-11 JP disclosed
US-4721725-A Aryl-cycloalkyl[b]pyrrole derivatives E. R. SQUIBB & SONS, INC. (US) 1988-01-26 US disclosed
EP-0238226-A1 Substituted 1,3,4,9-tetrahydropyrano [3,4-b]indole-1-acetic acids AMERICAN HOME PRODUCTS CORPORATION (US) 1987-09-23 EP disclosed
US-4670462-A ANTIINFLAMMATORY AND ANALGESIC AGENTS AMERICAN HOME PRODUCTS CORPORATION (US) 1987-06-02 US disclosed
EP-0022634-B1 ACYLATED INDOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS AND DRUGS COMPRISING THEM TEIJIN LIMITED (JP) 1983-04-06 EP disclosed
EP-0022634-A1 Acylated indole derivatives, processes for their preparation and pharmaceutical compositions and drugs comprising them TEIJIN LIMITED (JP) 1981-01-21 EP disclosed
EP-0022634-A1 Acylated indole derivatives, processes for their preparation and pharmaceutical compositions and drugs comprising them TEIJIN LIMITED (JP) 1981-01-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (24 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040038943-A1 Indole and benzimidazole 15-lipoxygenase inhibitors ALOX15, ALOX5, ALOX12 SLC6A4 2661/4885HTR2A 506/4885HTR1A 275/4885
US-20050119234-A1 Cannabimimetic indole derivatives CNR2, CNR1, HTR2C SLC6A4 140/4885HTR2A 8/4885HTR1A 16/4885
US-20060172019-A1 Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders CNR2, CNR1, GPER1 SLC6A4 3377/4885HTR2A 1698/4885HTR1A 1085/4885
US-20050124620-A1 Indole derivatives having an acidic moiety that inhibit or modulate activity of p38 map kinase mediating a disease state; e.g., 3-(2-(4-pyridyl)ethyl)-5-(3-trifluoromethoxybenzamido)indole; enzyme inhibitors; antiarthritic, -inflammatory, and -carcinogenic agents; respiratory disorders; AIDS; Alzheimer's MAPK1, IDO1, INMT SLC6A4 1190/4885HTR2A 1350/4885HTR1A 795/4885
US-20090281052-A1 Indole Antiviral Compositions And Methods IDO1, IDO2, MAVS SLC6A4 84/4885HTR2A 117/4885HTR1A 60/4885
US-20120270827-A1 Indole Antiviral Compositions And Methods IDO1, IDO2, MAVS SLC6A4 84/4885HTR2A 117/4885HTR1A 60/4885
US-20070082872-A1 Indole-containing compounds with anti-tubulin and vascular targeting activity TUBB3, TUBB1, TUBB SLC6A4 548/4885HTR2A 1788/4885HTR1A 1652/4885
US-20050009903-A1 CB2-selective cannabinoid analogues CNR2, CNR1, GPR68 SLC6A4 993/4885HTR2A 22/4885HTR1A 17/4885
US-10752585-B2 Process for the preparation of Zafirlukast and analogs thereof CHUK, HRH2, CTSH SLC6A4 2592/4885HTR2A 2084/4885HTR1A 1382/4885
US-20200223826-A1 Glucose-6-Phosphate Dehydrogenase (G6PD)-Modulating Agents And Methods Of Treating G6PD Deficiency G6PD, DPYD, G6PC1 SLC6A4 3617/4885HTR2A 2419/4885HTR1A 3901/4885
US-20080146517-A1 Indole Antiviral Compositions And Methods IDO1, IDO2, MAVS SLC6A4 84/4885HTR2A 117/4885HTR1A 60/4885
US-20050143329-A1 Indole antiviral compositions and methods IDO1, IDO2, MAVS SLC6A4 84/4885HTR2A 117/4885HTR1A 60/4885
US-10266526-B2 Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer SMYD3, SMYD2, SNRPD3 SLC6A4 1580/4885HTR2A 2794/4885HTR1A 3385/4885
US-20250382269-A1 METHODS AND COMPOSITIONS FOR SELECTIVELY INHIBITING PATHOGENIC MICROBES CD14, MIF, NOD2 SLC6A4 2870/4885HTR2A 4846/4885HTR1A 4485/4885
US-20170325457-A1 FORMULATIONS FOR THE DELIVERY OF ACTIVE AGENTS TO INSECTS, PLANTS, AND PLANT PATHOGENS NSF, GET3, SLC47A2 SLC6A4 979/4885HTR2A 4277/4885HTR1A 4591/4885
US-20170355695-A1 SMYD Inhibitors SMYD3, SMYD2, SMURF2 SLC6A4 1612/4885HTR2A 2608/4885HTR1A 3743/4885
US-20180312493-A1 Antibiotic Compounds, Pharmaceutical Formulations Thereof And Methods And Uses Therefor UGT1A8, CYP2C8, CXCL8 SLC6A4 4420/4885HTR2A 4829/4885HTR1A 3999/4885
US-20250382268-A1 METHODS AND COMPOSITIONS FOR SELECTIVELY INHIBITING PATHOGENIC MICROBES CD14, MIF, NOD2 SLC6A4 2870/4885HTR2A 4846/4885HTR1A 4485/4885
US-20080090871-A1 CANNABIMIMETIC INDOLE DERIVATIVES CNR2, CNR1, GPR34 SLC6A4 343/4885HTR2A 36/4885HTR1A 52/4885
US-20200216390-A1 PROCESS FOR THE PREPARATION OF ZAFIRLUKAST AND ANALOGS THEREOF CHUK, CTSH, HRH2 SLC6A4 2198/4885HTR2A 1941/4885HTR1A 1323/4885
US-20090318446-A1 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy ABL1, CDK2, JAK2 SLC6A4 1407/4885HTR2A 730/4885HTR1A 897/4885
US-20110065715-A1 Nogo Receptor Binding Small Molecules to Promote Axonal Growth NGFR, GAP43, BDNF SLC6A4 2391/4885HTR2A 1280/4885HTR1A 878/4885
US-20080275102-A1 3-ACYLINDOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF F12, ECI1, NQO2 SLC6A4 640/4885HTR2A 316/4885HTR1A 88/4885
US-20110178038-A1 Indole Antiviral Compositions And Methods IDO1, IDO2, MAVS SLC6A4 84/4885HTR2A 117/4885HTR1A 60/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.